Effects of electroacupuncture combined with paliperidone palmitate long-acting injection on withdrawal symptoms and neurotransmitters in methamphetamine addicts

被引:0
|
作者
Chen, Yu [1 ]
Wei, Wen-Jie [1 ]
Gong, Ji-Fen [1 ]
Qiao, Juan [1 ]
Wu, Chun-Xi [1 ]
Wang, Xiao-Jun [1 ]
Ding, Ying [1 ]
Chen, Hong-Yuan [1 ]
Lu, Hua-Xin [1 ]
Li, Ming-Chao [2 ]
Ji, Qiu-Ming [1 ]
机构
[1] Wuhan Wudong Hosp, Dept Psychiat, 46 Wudong St, Wuhan 430084, Peoples R China
[2] Wuhan Mental Hlth Ctr, Dept Psychiat, Wuhan, Peoples R China
关键词
Electroacupuncture treatment; methamphetamine; neurotransmitters; paliperidone palmitate long-acting injection; CLINICAL-PHARMACOLOGY; SCHIZOPHRENIA; NEUROTOXICITY;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
. Objective. To investigate the effects of electroacupuncture combined with paliperidone palmitate long-acting injection (PP-LAI) on withdrawal symptoms and neurotransmitters in methamphetamine (MA) addicts. Materials and methods. A total of 109 methamphetamine addicts, who were treated in the hospital from October 2021 to October 2022, were selected. According to the random number table, the patients were divided into the study group (n=54) and the control group (n=55), in which the control group was treated with PP-LAI and the study group was treated with electroacupuncture on the basis of the control group; the methamphetamine withdrawal symptom score scale was used to assess the therapeutic effect before treatment and within 12 months after treatment; the changes of brain neurotransmitters dopamine, gamma-aminobutyric acid, serotonin, acetylcholine values were compared between the two groups. Results .1) There was no statistical difference in MA withdrawal symptom scores between the two groups before treatment (p>0.05); 2) MA withdrawal symptom scores have a statistically significant difference between the study group and the control group after 3 and 6 months of treatment; 3) dopamine levels in the study group were significantly higher than those in the control group after 6 months of completion of treatment, and gamma-aminobutyric acid values and 5- serotonin values in the study group were significantly lower than those in the control group (p<0.05). Conclusions. Electroacupuncture combined with PP-LAI can partially improve the withdrawal symptoms and anxiety of methamphetamine addicts. This is a potential treatment for preventing relapse of withdrawal symptoms.
引用
收藏
页码:120 / 126
页数:7
相关论文
共 50 条
  • [21] In vitro and in vivo characterization of Invega Sustenna® (paliperidone palmitate long-acting injectable suspension)
    Li, Ji
    Rodriguez, Antonela
    Wang, Kaikai
    Olsen, Karl
    Wang, Yan
    Schwendeman, Anna
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2025, 207
  • [22] Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization
    Taylor, David
    Olofinjana, Olubanke
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (04) : 229 - 234
  • [23] Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
    Mahlich, Jorg
    Nishi, Masamichi
    Saito, Yoshimichi
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 267 - 272
  • [24] Bilateral Pretibial Edema Associated with Paliperidone Palmitate Long-acting Injectable: A Case Report
    Cicek, Erdinc
    Cicek, Ismet Esra
    Uguz, Faruk
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2017, 15 (02) : 184 - 186
  • [25] Effects of Long-acting Injectable 3-Monthly Paliperidone Palmitate on the Clinical and Social Performance of Patients with Schizophrenia
    Oh, Jihoon
    Oh, Jihye
    Kim, Dong Wook
    Youn, HyunChul
    Kim, Sae-Hoon
    Kim, Soo In
    Chung, In Won
    Wang, Kuan Shu
    Kim, Minah
    Paik, Jong -Woo
    Koh, Min Jung
    Lee, Yoosun
    Choi, Seok Young
    Kim, Jung-Jin
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2023, 21 (01) : 126 - 134
  • [26] A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder
    Chue, Pierre
    Chue, James
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 109 - 116
  • [27] Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison
    Fu, Dong-Jing
    Bossie, Cynthia A.
    Sliwa, Jennifer K.
    Ma, Yi-Wen
    Alphs, Larry
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (01) : 45 - 55
  • [28] Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia : A Critical Appraisal
    Garcia-Carmona, Juan Antonio
    Pappa, Sofia
    DRUG HEALTHCARE AND PATIENT SAFETY, 2023, 15 : 113 - 123
  • [29] Effectiveness of paliperidone palmitate one-month long-acting injection in obese vs. non-obese patients
    Dorflinger, Charles
    LeHew, Colleen
    Carey, Heather
    Roche-Desilets, Jennifer
    Burant, Christopher J.
    COMPREHENSIVE PSYCHIATRY, 2021, 111
  • [30] Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients Results From a Multicenter Retrospective Cohort Study in France
    Limosin, Frederic
    Belhadi, Drifa
    Comet, Denis
    Pacou, Maud
    Bouju, Sophie
    Van Impe, Kristel
    Guillon, Pascal
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2018, 38 (01) : 19 - 26